Stage (next event)
Phase 1/2 (Top-line Data)
Catalyst Info & Data Links
TITLE: for COVID-19 - Phase 1/2 Top-line Data
ClinicalTrial.gov (NCT04550325): Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19
WHAT IS THE NEXT CATALYST EVENT?
Phase 1/2 Top-line Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
09-08-2020 Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)
Mechanism of Action
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post